Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
NCT ID NCT03042468
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lower PSA levels. About 50 men are participating in this early-phase study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If it works, this could provide a new, targeted treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to everyone. The drug is radioactive and may cause side effects like dry mouth, fatigue, or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tulane Cancer Center Clinic
New Orleans, Louisiana, 70112, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States